TABLE 1.
Comparison of demographic data among ND, AD, VaD, and DLB groups.
| Groups | ND | AD | VaD | DLB | F/x2 | p |
| N | 190 | 230 | 183 | 63 | ||
| Age, year | 68.1 ± 11.4 | 80.1 ± 8.6 | 73.7 ± 10.7 | 80.8 ± 7.0 | 57.24 | <0.001 |
| Female, N (%) | 100 (52.6) | 154 (67.0) | 77 (42.1) | 36 (57.1) | 29.19 | <0.001 |
| Education, year | 7.4 ± 4.9 | 4.4 ± 4.5 | 6.0 ± 4.8 | 5.3 ± 13.0 | 9.15 | <0.001 |
| CDR, 0/0.5/1/2/3 | 53/137/0/0/0 | 0/85/77/51/17 | 0/66/52/48/17 | 0/9/22/20/12 | 324.18 | <0.001 |
| CDR-SB | 0.7 ± 0.7 | 6.7 ± 4.4 | 7.2 ± 5.0 | 9.7 ± 5.2 | 128.61 | <0.001 |
| IADL | 7.7 ± 0.6 | 2.7 ± 2.7 | 2.6 ± 2.9 | 1.4 ± 2.3 | 235.16 | <0.001 |
| MoCA | 20.0 ± 6.0 | 7.4 ± 5.5 | 9.1 ± 6.8 | 7.1 ± 6.5 | 175.02 | <0.001 |
| CASI | 81.5 ± 12.1 | 44.8 ± 21.5 | 47.8 ± 24.6 | 43.2 ± 23.3 | 139.26 | <0.001 |
| NPI-sum | 3.4 ± 5.0 | 5.2 ± 6.9 | 8.3 ± 9.3 | 15.6 ± 14.0 | 31.02 | <0.001 |
| UPDRS-M | 7.1 ± 7.1 | 11.4 ± 12.0 | 30.6 ± 14.6 | 28.9 ± 11.1 | 37.76 | <0.001 |
| DLB features, N (%) | ||||||
| Fluctuation | 4 (2.1) | 32 (13.9) | 48 (26.2) | 32 (50.8) | 91.61 | <0.001 |
| VH | 1 (0.5) | 10 (4.3) | 16 (8.7) | 29 (46.0) | 136.07 | <0.001 |
| Parkinsonism | 32 (16.8) | 42 (18.3) | 73 (39.9) | 59 (93.7) | 157.39 | <0.001 |
| RBD | 17 (8.9) | 13 (5.7) | 13 (7.1) | 34 (54.0) | 123.49 | <0.001 |
| DaTabN | 2 (6.9) | 3 (20.0) | 8 (47.1) | 19 (79.2) | 31.94 | <0.001 |
| Informant | ||||||
| Age, year | 58.8 ± 13.3 | 54.9 ± 14.3 | 55.7 ± 13.7 | 54.3 ± 13.7 | 1.96 | 0.120 |
| Education, year | 11.1 ± 7.5 | 11.1 ± 4.3 | 10.2 ± 4.8 | 11.1 ± 4.9 | 0.60 | 0.613 |
N, Number of participants; ND, Non-demented; AD, Alzheimer disease; VaD, vascular dementia; DLB, Dementia with Lewy bodies; CDR, Clinical Dementia Rating; IADL, Instrumental Activities of Daily Living; MoCA, Montreal Cognitive Assessment; CASI, Cognitive Abilities Screening Instrument; NPI-sum, The sum of score of Neuropsychiatric Inventory; UPDRS-M, motor subscale of the Unified Parkinson’s Disease Rating Scale in 28 NC, 34 AD, 34 VCI, and 25 DLB; VH, visual hallucinations; RBD, REM sleep behavior disorder; DaTabN, abnormal dopamine transporter imaging in 29 NC, 15 AD, 17 VCI, and 24 DLB.